Andrew Hollman Meyer sold $732k of JANX
Chief Business Officer at Janux Therapeutics, Inc.. 13,334 shares at an average of $54.88, traded Jan 2, 2025, filed Jan 3, 2025.
Score components
- +15RoleOfficer
- +21Trade size$732k at market
- +5Share of holdings soldSold 14% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001415889-25-000554, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 2, 2025 | AGrant or award Common Stock | +18,000 | $0.00 | $0 | 95,473 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -2,922 | $53.76 | $157k | 92,551 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -5,768 | $54.51 | $314k | 86,783 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -3,444 | $55.76 | $192k | 83,339 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -1,000 | $56.78 | $57k | 82,339 | Jan 3, 2025 |
| Jan 2, 2025 | SOpen-market sale Common Stock10b5-1 | -200 | $57.37 | $11k | 82,139 | Jan 3, 2025 |
| Jan 2, 2025 | AGrant or award Stock option (right to buy)derivative | +63,000 | $0.00 | $0 | 63,000 | Jan 3, 2025 |
Related signals
Other insiders at Janux Therapeutics, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 43Moderate | JANXbuy Janux Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $25M 824,041 shares | +9% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $107k 3,334 shares | -4% | |
| 0Weak | Janux Therapeutics, Inc. | Andrew Hollman Meyer Chief Business Officer | $141k 3,334 shares | -4% | |
| 27Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $300k 5,000 shares | -2% | |
| 43Moderate | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.4M 25,000 shares | -10% | |
| 30Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.0M 15,000 shares | -6% | |
| 30Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.3M 25,000 shares | -9% | |
| 38Weak | Janux Therapeutics, Inc. | David Alan Campbell President and CEO | $1.3M 25,000 shares | -8% | |
| 19Weak | JANXsell Janux Therapeutics, Inc. | Jay Lichter owner | $178k 3,815 shares | -35% | |
| 43Moderate | JANXbuy Janux Therapeutics, Inc. | Ra Capital Management, L.p. director, owner | $54M 1,200,000 shares | +15% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.